​​​​​Stellenbosch University Immunology Research Group

Publications

2006

1. TB epidemiology and human genetics.

van Helden PD, Möller M, Babb C, Warren R, Walzl G, Uys P, Hoal E. Novartis Found Symp. 2006;279:17-31; discussion 31-41, 216-9. Review.

http://www.ncbi.nlm.nih.gov/pubmed/17278383

2. Antimicrobial resistance in tuberculosis: an international perspective.

van Helden PD, Donald PR, Victor TC, Schaaf HS, Hoal EG, Walzl G, Warren RM. Expert Rev Anti Infect Ther. 2006 Oct;4(5):759-66. Review.

 http://www.ncbi.nlm.nih.gov/pubmed/17140353

3. Immune markers measured before treatment predict outcome of intensive phase tuberculosis therapy.

Brahmbhatt S, Black GF, Carroll NM, Beyers N, Salker F, Kidd M, Lukey PT, Duncan K, van Helden P, Walzl G. Clin Exp Immunol. 2006 Nov;146(2):243-52.

http://www.ncbi.nlm.nih.gov/pubmed/17034576

4. Changes in leucocyte and lymphocyte subsets during tuberculosis treatment; prominence of CD3dimCD56+ natural killer T cells in fast treatment responders.

Veenstra H, Baumann R, Carroll NM, Lukey PT, Kidd M, Beyers N, Bolliger CT, van Helden PD, Walzl G. Clin Exp Immunol. 2006 Aug;145(2):252-60.

http://www.ncbi.nlm.nih.gov/pubmed/16879244

5. Role of CCL5 (RANTES) in viral lung disease.

Culley FJ, Pennycook AM, Tregoning JS, Dodd JS, Walzl G, Wells TN, Hussell T, Openshaw PJ. J Virol. 2006 Aug;80(16):8151-7.

http://www.ncbi.nlm.nih.gov/pubmed/16873271

6. Recall of intestinal helminthiasis by HIV-infected South Africans and avoidance of possible misinterpretation of egg excretion in worm/HIV co-infection analyses.

Adams VJ, Markus MB, Kwitshana ZL, Dhansay MA, van der Merwe L, Walzl G, Fincham JE. BMC Infect Dis. 2006 May 26;6:88.

http://www.ncbi.nlm.nih.gov/pubmed/16725057​